Effect of topical phosphodiesterase 4 inhibitor E6005 on Japanese children with atopic dermatitis: Results from a randomized, vehicle-controlled exploratory trial

Journal of Dermatology

Volumn 43, Issue 8, 2016, Pages 881-887

  Nemoto, Osamu ^a   Hayashi, Nobukazu ^b   Kitahara, Yasumi ^c   Furue, Masutaka ^d   Hojo, Seiichiro ^c   Nomoto, Maiko ^c   Shima, Satoshi ^c   Asanuma, Hiroyuki ^e   Saga, Kenji ^e   Takahashi, Yoshimasa ^e   Morikawa, Reiko ^e   Hagiwara, Kazuya ^e   Sugawara, Hiroshi ^e   Takata, Hideyasu ^e   Etoh, Takafumi ^e  

^a Sapporo Skin Clinic   (Japan)

^b TORANOMON HOSPITAL   (Japan)

^c EISAI CO LTD   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

^e NONE

Author keywords

atopic dermatitis; children; E6005; phosphodiesterase 4 inhibitor; topical drug

Indexed keywords

E 6005; PHOSPHODIESTERASE IV INHIBITOR; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ARTICLE; ATOPIC DERMATITIS; CHILD; CHILD HEALTH CARE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; EXPLORATORY RESEARCH; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRURITUS; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84980348067     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/1346-8138.13231     Document Type: Article

References (23)

1. Kabashima K. New concept of the pathogenesis of atopic dermatitis: interplay among the barrier, allergy, and pruritus as a trinity. J Dermatol Sci 2013; 70: 3–11.
2. Akdis CA, Akdis M, Bieber T et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. Allergy 2006; 61: 969–987.
3. Saeki H, Furue M, Furukawa F et al. Guidelines for management of atopic dermatitis. J Dermatol 2009; 36: 563–577.
4. Draelos ZD. Use of topical corticosteroids and topical calcineurin inhibitors for the treatment of atopic dermatitis in thin and sensitive skin areas. Curr Med Res Opin 2008; 24: 985–994.
5. Hengge UR, Ruzicka T, Schwartz RA et al. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 2006; 54: 1–15.
6. Ishii N, Shirato M, Wakita H et al. Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model. J Pharmacol Exp Ther 2013; 346: 105–112.
7. Wakita H, Ohkuro M, Ishii N et al. A putative antipruritic mechanism of the phosphodiesterase-4 inhibitor E6005 by attenuating capsaicin-induced depolarization of C-fiber nerves. Exp Dermatol 2015; 24: 215–216.
8. Andoh T, Yoshida T, Kuraishi Y. Topical E6005, a novel phosphodiesterase 4 inhibitor, attenuates spontaneous itch-related responses in mice with chronic atopy-like dermatitis. Exp Dermatol 2014; 23: 359–361.
9. Furue M, Kitahara Y, Akama H et al. Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis: results of a randomized, vehicle-controlled, multicenter clinical trial. J Dermatol 2014; 41: 577–585.
10. Long CC, Mills CM, Finlay AY. A practical guide to topical therapy in children. Br J Dermatol 1998; 138: 293–296.
11. Wilhelm AJ, den Burger JC, Swart EL. Therapeutic drug monitoring by dried blood spot: progress to date and future directions. Clin Pharmacokinet 2014; 53: 961–973.
12. Mano Y, Ishii T, Hotta K et al. Validation of a UPLC-MS/MS method for the simultaneous determination of E6005, a phosphodiesterase 4 inhibitor, and its metabolite in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2015; 998–999: 31–39.
13. Hanifin JM, Thurston M, Omoto M et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol 2001; 10: 11–18.
14. Barbier N, Paul C, Luger T et al. Validation of the eczema area and severity index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme. Br J Dermatol 2004; 150: 96–102.
15. Eichenfield L, Lucky A, Boguniewicz M et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002; 46: 495–504.
16. Marini A, Reinelt K, Krutmann J et al. Ectoine-containing cream in the treatment of mild to moderate atopic dermatitis: a randomised, comparator-controlled, intra-individual double-blind, multi-center trial. Skin Pharmacol Physiol 2014; 27: 57–65.
17. Boguniewicz M, Fiedler VC, Raimer S et al. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. J Allergy Clin Immunol 1998; 102: 637–644.
18. Reitamo S, Van Leent EJ, Ho V et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol 2002; 109: 539–546.
19. Reitamo S, Harper J, Bos JD et al. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial. Br J Dermatol 2004; 150: 554–562.
20. Doss N, Kamoun MR, Dubertret L et al. Efficacy of tacrolimus 0.03% ointment as second-line treatment for children with moderate-to-severe atopic dermatitis: evidence from a randomized, double-blind non-inferiority trial vs. fluticasone 0.005% ointment. Pediatr Allergy Immunol 2010; 21: 321–329.
21. Zhu HJ, Appel DI, Jiang Y et al. Age- and sex-related expression and activity of carboxylesterase 1 and 2 in mouse and human liver. Drug Metab Dispos 2009; 37: 1819–1825.
22. Ishii N, Wakita H, Shirato M. Effect of the phosphodiesterase 4 inhibitor E6005 on nerve growth factor elevation in irritated skin of NC/Nga mice. J Dermatol Sci 2014; 76: 263–264.
23. Andoh T, Kuraishi Y. Antipruritic mechanisms of topical E6005, a phosphodiesterase 4 inhibitor: inhibition of responses to proteinase-activated receptor 2 stimulation mediated by increase in intracellular cyclic AMP. J Dermatol Sci 2014; 76: 206–213.